What's behind Abbott's latest 10.1% stock surge?

Traders Union
All News
Financial News
Abbott Laboratories surges 10.07% today

Highlights

Abbott Laboratories exceeded earnings expectations in Q2 2026 with adjusted EPS of $1.31 and raised its full-year EPS outlook.
The company completed its acquisition of Exact Sciences to strengthen its cancer diagnostics platform, while medical devices and diabetes care maintained growth momentum.
Despite a volatile 10% intraday gain and signals of near-term oversold conditions, technicals suggest price consolidation between $94.75 and $111.20 over the coming sessions.

Earnings, guidance boost offset by revenue miss and business expansion

Abbott Laboratories reported second-quarter 2026 adjusted earnings of $1.31 per share, surpassing analyst estimates. The company's quarterly revenue reached $12.59 billion, slightly below consensus, and it raised full-year EPS guidance. Abbott returned $2.1 billion to shareholders through dividends and share repurchases, completed its acquisition of Exact Sciences to expand its cancer diagnostics business, and posted ongoing growth in its medical devices and diabetes care units.

Anton Kharitonov, expert at Traders Union, notes that Abbott’s strong Q2 earnings and strategic moves have failed to break persistent long-term technical resistance. He sees warning signs in the stock’s inability to recover above its 200-day moving average, despite attracting buyers with upbeat news and capital returns. Mixed momentum readings and oversold signals imply that the surge may be overextended amid underlying seller dominance. Kharitonov is skeptical of lasting upside given the 68% probability of a downward move and continued volatility. "Abbott needs to decisively reclaim higher levels before I’d turn constructive — otherwise, this rally looks unsustainable in the face of ongoing resistance."

Viktoras Karapetjanc, expert at Traders Union, believes Abbott’s operational gains and upward EPS revision reinforce solid fundamentals. The completed Exact Sciences acquisition and robust device growth support a bullish setup and sector leadership. He sees the recent buyback and dividend activity as strong shareholder signals, positioning Abbott for outperformance if technical hurdles clear. Karapetjanc states, "With momentum improving and strategy execution on track, I expect the bullish structure to remain intact and further growth to follow if resistance at $101.66 breaks."

Jainam Mehta, market strategist, points to the contrast between intraday gains and the mixed momentum landscape. He notes price volatility creates tactical opportunities, especially as the stock settles between key levels. Mehta suggests that divergence across technical indicators could lead to a potential breakout or swing reversal. "The best risk-adjusted setup favors short-term range trades until price convincingly chooses direction beyond $101.66 or $94.75."

Short-term strength clashes with lingering pressure and mixed momentum

Abbott is trading above its 20-day ($91.99) and 50-day ($89.15) moving averages, confirming recent short- and medium-term strength, but remains below the 200-day level ($110.17), indicating lingering long-term pressure from sellers. Near-term support sits at the session low of $94.99, with the session high of $101.66 as immediate resistance; the Ichimoku Kijun at $92.64 aligns with the prevailing trend as a distant confirmation of underlying support. Momentum readings are mixed: the Moving Average Convergence Divergence (MACD) shows a strong buy signal, yet the Average Directional Index (ADX) remains neutral. Both the Relative Strength Index (RSI) at 42.89 and Commodity Channel Index (CCI) at -94.72 suggest the stock is leaning toward oversold territory, echoed by extremely low Stochastic RSI and a negative Bull/Bear Power (BBP) value, which indicate sellers dominate intraday momentum and forecast an oversold bias. Despite these undervalued signals, Abbott has surged $8.99 or 10.07% so far today following a pronounced upside gap of approximately $5.72 (6.41%), with the stock now mid-range between its intraday high and low after volatility of 7.02%. The intraday tone suggests early strength followed by some stabilization, alongside clear divergence between momentum indicators and the day's sharp move.

Earlier, analysts noted that Abbott faced sustained bearish momentum and technical resistance, with caution prevailing among traders. The current reversal, underpinned by earnings strength and a pronounced upside gap, introduces a potential shift in sentiment; traders should monitor whether the stock can maintain momentum above $101.66 to confirm a sustained breakout from its previous downtrend.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.